Topic
Topic
Phase 3 extension data show denifanstat, an oral fatty acid synthase inhibitor, sustained acne improvement through 52 weeks — the longest durability readout for the agent to date.
Phase 3 data show lebrikizumab improved atopic dermatitis symptoms and itch in children, extending IL-13 inhibition evidence into…
Merck posts the first positive Phase 3 result for a personalized mRNA melanoma therapy, advancing individualized neoantigen immun…
Phase 3 head-to-head data show once-daily zasocitinib achieved superior skin clearance versus deucravacitinib in plaque psoriasis…
Zasocitinib showed superior efficacy versus deucravacitinib in Phase 3 head-to-head psoriasis data, with rapid, durable clearance…
Barzolvolimab, a KIT-targeting monoclonal antibody, met all primary and secondary end points in a Phase 3 chronic spontaneous urt…
Regeneron shares dropped after a skin cancer treatment failed a late-stage trial. Details on the drug, indication and endpoint pe…
